Launch a new com­pa­ny, steer a $150M IPO and ink a big da­ta col­lab­o­ra­tion — they call it Mon­day at Vivek Ra­maswamy’s Roivant

Vivek Ra­maswamy’s first Phase III may have been a nasty fail­ure, but there’s no sign it’s slowed him down one tiny bit. We have three new moves to re­port this morn­ing in­volv­ing a new up­start in the ranks, a big IPO and a da­ta deal with a big CRO.

Let’s start with the new biotech.

A year af­ter the team at Patara Phar­ma tout­ed the re­sults of a Phase IIa study for their lead drug to treat chron­ic cough in IPF pa­tients, they’ve packed up shop and tak­en their pro­gram to join up with the fast-grow­ing crew at Vivek Ra­maswamy’s Roivant Sci­ences.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER